Nurix Therapeutics, Inc. Initial Public Offering

Davis Polk advised the underwriters in connection with an initial public offering of 11,000,000 shares of common stock of Nurix Therapeutics, Inc. at $19 per share, for total gross proceeds of $209 million. The common stock is listed on the Nasdaq Global Market under the symbol “NRIX.”

Based in San Francisco, California, Nurix Therapeutics is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders.

The Davis Polk corporate team included partners Alan F. Denenberg and Emily Roberts and associates Jonathan Bye and Sherry Tan. The intellectual property and technology transactions team included partner David R. Bauer and associates Gianna C. Walton and Marisa Elena Bannon. The tax team included partner Michael Farber and associate Daniel L. Jose. Counsel Marcie A. Goldstein provided FINRA advice. Members of the Davis Polk team are based in the Northern California and New York offices.